本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对本公司当期业绩无重大影响。 格隆汇11月19日丨白云山(600332.SH)公布，公司全资子公司广州白云山中一药业有限公司（简称"中一 药业"）收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。安宫牛黄丸的功能主治为清热解 毒，镇惊开窍。 ...

每经AI快讯，11月19日，白云山(600332.SH)公告称，全资子公司中一药业收到越南卫生部传统药品管 理局签发的安宫牛黄丸注册证书。该药品将由中一药业授权TNHHNEWSEENCOAST公司在越南地区销 售，有助于扩展越南市场业务。但对公司当期业绩无重大影响，且医药产品销售受市场环境变化影响， 存在不确定性。 ...

白云山公告，全资子公司广州白云山中一药业有限公司收到越南卫生部传统药品管理局签发的安宫牛黄 丸注册证书。中一药业于2024年6月20日向越南卫生部传统药品管理局递交了药品注册申请。安宫牛黄 丸的功能主治为清热解毒，镇惊开窍。根据米内网数据显示，2024年中一药业安宫牛黄丸的销售收入为 人民币1.56亿元。在药品研发项目上已累计投入研发费用合计约人民币3279.81万元（未审计）。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600713 证券简称：南京医药 编号：ls2025-141 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于简式权益变动报告书修订说明的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2025年9月26日，南京医药股份有限公司（以下简称"公司"或"南京医药"）第二大股东Alliance Healthcare Asia Pacific Limited（以下简称"Alliance Healthcare"）与广州广药二期基金股权投资合伙企业 （有限合伙）（以下简称"广药二期基金"）签署《关于南京医药股份有限公司 11.04%股份的股份转让 合同》，将其持有的全部144,557,431股（以下简称"目标股份"）公司股份（占公司目前总股本的 11.04%）转让给广药二期基金，转让价格为5.18元/股（人民币，下同），转让总金额为748,807,492.58 元。本次权益变动完成后，Alliance Healthcare将不再持有公司股份，广药二期 ...

1 本次交易尚需上海证券交易所进行合规性确认后方能办理股份过户 等手续，最终能否实施并完成交易尚存在不确定性。本公司将持续关注本 次交易进展，并严格按照有关法律、法规要求及时履行信息披露义务。敬 请广大投资者理性投资，注意投资风险。 证券代码：600332 证券简称：白云山 公告编号：2025－078 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药股份有限公司 11.04%股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开第九届董事会第二十九次会议，审议通过了《关于广州广药二期基金 股权投资合伙企业（有限合伙）收购南京医药股份有限公司 11.04%股份 的议案》。本公司附属企业广州广药二期基金股权投资合伙企业（有限合 伙）（"广药二期基金"）拟以自有资金通过协议转让方式收购 Alliance Healthcare Asia Pacific Limited（"AH ...

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合夥）收購南京醫藥股份有限公司11.04%股權 的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown a mixed performance in financing activities and stockholder dynamics, with a slight increase in revenue and net profit year-on-year, indicating stable growth in its core business segments [1][2][3] Financing Activities - On November 11, Baiyunshan's financing buy-in amounted to 21.89 million yuan, while financing repayment reached 35.18 million yuan, resulting in a net financing outflow of 13.30 million yuan [1] - The total financing and securities balance for Baiyunshan as of November 11 is 859 million yuan, with the financing balance accounting for 2.23% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 1,000 shares and sold 11,000 shares on November 11, with the selling amount calculated at 301,100 yuan, and the remaining securities lending balance is 8.10 million shares [1] Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management [2] - The company's revenue composition shows that the major commercial segment contributes 69.32%, followed by health products at 16.79%, and traditional medicine at 12.53% [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up by 4.78% [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have seen a decrease in their holdings compared to the previous period [3]

Core Insights - The article discusses the recent developments in the pharmaceutical industry, particularly focusing on the performance and strategic moves of a specific company in the sector [2] Group 1: Company Performance - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion in the last quarter [2] - The net profit margin improved to 20%, up from 17% in the previous year, indicating better cost management and operational efficiency [2] - The company has expanded its product line, launching three new drugs that are expected to contribute an additional $300 million in revenue over the next year [2] Group 2: Market Trends - The pharmaceutical industry is experiencing a shift towards personalized medicine, with a projected market growth rate of 10% annually [2] - Regulatory changes are anticipated to streamline the approval process for new drugs, potentially reducing time-to-market by 25% [2] - Increased investment in biotechnology is driving innovation, with venture capital funding in the sector reaching $10 billion in the last year [2]

Group 1 - The core point of the article is that JPMorgan has increased its stake in Guangzhou Pharmaceutical Holdings (00874) by purchasing 267,243 shares at a price of HKD 18.9038 per share, totaling approximately HKD 5.0519 million [1] - After the purchase, JPMorgan's total shareholding in Guangzhou Pharmaceutical Holdings is approximately 17,699,300 shares, representing a holding percentage of 8.04% [1]

Group 1 - The core point of the article is that JPMorgan has reduced its stake in China National Pharmaceutical Group (Baiyunshan) by selling 117,475 shares at a price of HKD 18.9589 per share, totaling approximately HKD 2.2272 million [1] - After the reduction, JPMorgan's remaining shareholding is approximately 17.5819 million shares, representing a holding percentage of 7.99% [1]